Markets
markets

Oscar Health slips after earnings miss

Oscar Health tumbled as much as 6% in premarket trading after it reported earnings that missed Wall Street estimates even after giving investors a look under the hood last month.

The company posted a diluted loss per share of $0.89, more than the $0.81 loss per share analysts polled by FactSet were expecting. The company attributed that to higher-than-expected medical costs.

Oscar also reported $2.81 billion in revenue, less than the $2.91 billion the Street was penciling in.

The company released preliminary earnings results on July 22 in which it flipped its forecast from expecting operating earnings of $250 million to an operating loss of $250 million. The revision came after it was hit with significantly higher costs of care for members on government-sponsored insurance.

Oscar is one of the last of its peers in the medical insurance business to report earnings. Companies that rely more on government-sponsored programs, like Centene and Elevance Health, have reported results that disappointed Wall Street while those that focus on private plans, like Cigna, have fared better.

Oscar, which has attracted retail attention in recent months, is up about 2% for the year as of market close on Tuesday.

More Markets

See all Markets
markets

Rare earth stocks are Wall Street’s hottest trade right now, so much so that MP Materials’ stock traded more than JPMorgan yesterday

Rare earth stocks are having a blast at the moment. The latest flashpoint of US-China trade relations, small stocks in the critical and rare earth minerals sector have ripped — but the trade went into overdrive to start this week.

After JPMorgan announced a $10 billion plan to directly invest in key industries like critical minerals, the sector spiked again on Monday, as traders responded to the news and continued to bet on the US government’s ongoing support for the nascent sector. In the announcement, Jamie Dimon, JPMorgan’s CEO, wrote that “the United States has allowed itself to become too reliant on unreliable sources of critical minerals, products, and manufacturing.”

One name in particular, MP Materials, soared 21% yesterday, with an eye-watering $4.7 billion worth of the stock trading in a single session — ironically, that’s even more than the $3.3 billion that changed hands in JPMorgan stock.

Still finding gold

Remarkably, the rare earth trade doesn’t seem to be losing any steam this morning.

As of 7 a.m. ET, MP Materials is up 5%. With risk-off sentiment dominating the premarket session — the US and China just rolled out their tit-for-tat port fees — the one winner from the trade tensions seems to still be the rare earth stocks. Indeed, other names in the industry are also trading higher, most notably United States Antimony Corp., Critical Metals, American Battery Technology Co., and USA Rare Earth.

markets

Navitas Semiconductor spikes after unveiling products “purpose-built” for Nvidia’s upcoming data center architecture

Shares of tiny chip firm Navitas Semiconductor are spiking after management unveiled products “purpose-built for Nvidia’s 800 VDC AI factory architecture, delivering breakthrough efficiency, power density, and performance.”

Nvidia is aiming to transition to 800-volt direct current power for its Kyber racks, which it expects to start deploying in 2027, and once again name-dropped Navitas as a partner in providing silicon in a blog post on Monday.

Navitas’ integrated circuits and silicon carbide chips are being positioned as ways to help make data center environments more space and power efficient.

“As NVIDIA drives transformation in AI infrastructure, we’re proud to support this shift with advanced GaN and SiC power solutions that enable the efficiency, scalability, and reliability required by next-generation data centers,” said Navitas CEO and President Chris Allexandre.

Navitas more than doubled on May 22 after announcing that it had earned a place in Nvidia’s supply chain, gaining 164% in its best session on record.

Its worst session since that revelation came in the wake of its second-quarter earnings report, where management provided an outlook for third-quarter sales that was both lower than expectations and lower than what they’d booked in Q2.

The takeaway back then was simply that the Nvidia halo effect wouldn’t be translating into actual sales imminently. The market’s takeaway today seems to be increased confidence in an eventual financial benefit from its relationship with the $4-trillion chip designer.

Tiny Scientists in Lab

String of acquisitions fuels biotech optimism

In the past month, the S&P Biotech ETF surpassed March 2020 levels.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.